Catalog No.
DHD80901
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Chimeric
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
CD30L receptor, Ki-1 antigen, CD30, TNFRSF8, D1S166E, Tumor necrosis factor receptor superfamily member 8, Lymphocyte activation antigen CD30
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P28908
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
SGN-35, cAC10-Val-Cit-MMAE, CAS: 914088-09-8, 2088770-90-3
Clone ID
Brentuximab
Brentuximab vedotin in T-cell lymphoma, PMID: 30526166
Brentuximab Vedotin: A Review in CD30-Positive Hodgkin Lymphoma, PMID: 28190142
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial, PMID: 25796459
Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study, PMID: 31945149
Brentuximab vedotin in the treatment of CD30+ PTCL, PMID: 31697814
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial, PMID: 28600132
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review, PMID: 28010897
Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma, PMID: 22454421
Brentuximab vedotin, PMID: 22684302
Brentuximab Vedotin in the Treatment of Peripheral T Cell Lymphoma and Cutaneous T Cell Lymphoma, PMID: 32016790
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin, PMID: 24652992
Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma, PMID: 31186274
Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study, PMID: 31398081
Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial, PMID: 33010817
Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma, PMID: 28974506
Brentuximab vedotin and its use in the treatment of advanced Hodgkin's lymphoma, PMID: 32677451
Brentuximab vedotin, PMID: 21410298
Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin's lymphoma: an international, multicentre, single-arm, phase 1-2 trial, PMID: 29276022
FDA Approval Summary: Brentuximab Vedotin in First-Line Treatment of Peripheral T-Cell Lymphoma, PMID: 30914464
Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study, PMID: 30290902
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study, PMID: 22614995
Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial, PMID: 32853585
Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO Group), PMID: 30657848
Brentuximab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone as frontline treatment for patients with CD30-positive B-cell lymphomas, PMID: 32414850
Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine in patients with advanced-stage, classical Hodgkin lymphoma: A prespecified subgroup analysis of high-risk patients from the ECHELON-1 study, PMID: 33462822
Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?, PMID: 33409966
Brentuximab vedotin, PMID: 25293772
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL, PMID: 29038340
PET-adapted sequential salvage therapy with brentuximab vedotin followed by augmented ifosamide, carboplatin, and etoposide for patients with relapsed and refractory Hodgkin's lymphoma: a non-randomised, open-label, single-centre, phase 2 study, PMID: 25683846
Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study, PMID: 32273476
Brentuximab vedotin for relapsed or refractory Hodgkin's lymphoma, PMID: 25848209
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma, PMID: 27432875
Brentuximab vedotin in Hodgkin's lymphoma, PMID: 22937794
A safety evaluation of brentuximab vedotin for the treatment of Hodgkin lymphoma, PMID: 27139729
Brentuximab vedotin: an anti-CD30 antibody-drug conjugate, PMID: 23515511
An evaluation of brentuximab vedotin as a treatment option for stage III/IV Hodgkin lymphoma, PMID: 31432732
Brentuximab vedotin, PMID: 22212672
Primary prophylaxis with G-CSF may improve outcomes in patients with newly diagnosed stage III/IV Hodgkin lymphoma treated with brentuximab vedotin plus chemotherapy, PMID: 32842815
Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous transplant: meta-analysis versus historical data, PMID: 25772232
[Brentuximab vedotin for previously untreated systemic anaplastic large cell lymphoma], PMID: 33308986
Brentuximab vedotin for the treatment of Hodgkin's lymphoma, PMID: 25967932
[Brentuximab vedotin: new treatment for CD30+ lymphomas], PMID: 23831822
Brentuximab vedotin treatment associated with acute and chronic inflammatory demyelinating polyradiculoneuropathies, PMID: 32327451
[Brentuximab vedotin and immune checkpoint inhibitors for the treatment of Hodgkin lymphoma], PMID: 32908053
Brentuximab Vedotin for Relapsed or Refractory Sézary Syndrome, PMID: 33377934
Brentuximab vedotin for lymphoma in paediatric patients, PMID: 30290898
Optimizing the role of brentuximab vedotin in classical Hodgkin lymphoma therapy, PMID: 30504312
Brentuximab vedotin: unexpectedly good response in CD30 - mycosis fungoides, PMID: 31157447
Brentuximab Vedotin (SGN-35), an antibody-drug conjugate for the treatment of CD30-positive malignancies, PMID: 22127011
Brentuximab vedotin for treatment of relapsed or refractory malignant lymphoma: results of a systematic review and meta-analysis of prospective studies, PMID: 25945039
For research use only. Not for human or drug use.
